The association aims to develop and implement smart imaging biomarkers to better understand the mechanism of action (MOA) of oncology drugs and collect more evidence of efficiency in early phase clinical trials.The agreement strengthens Median’s iCRO capabilities to support the biopharmaceutical industry’s move towa...